Abstract:In the advanced stages of cancers like melanoma, some of the malignant cells leave the primary tumor and infiltrate the neighboring lymph nodes (LNs). The interaction between secondary cancer and the immune response in the lymph node represents a complex process that needs to be fully understood in order to develop more effective immunotherapeutic strategies. In this process, antigen-presenting cells (APCs) approach the tumor and initiate the adaptive immune response for the corresponding antigen. They stimulate the naive CD4+ and CD8+ T lymphocytes which subsequently generate a population of helper and effector cells. On one hand, immune cells can eliminate tumor cells using cell-cell contact and by secreting apoptosis inducing cytokines. They are also able to induce their dormancy. On the other hand, the tumor cells are able to escape the immune surveillance using their immunosuppressive abilities. To study the interplay between tumor progression and the immune response, we develop two new models describing the interaction between cancer and immune cells in the lymph node. The first model consists of partial differential equations (PDEs) describing the populations of the different types of cells. The second one is a hybrid discrete-continuous model integrating the mechanical and biochemical mechanisms that define the tumor-immune interplay in the lymph node. We use the continuous model to determine the conditions of the regimes of tumor-immune interaction in the lymph node. While we use the hybrid model to elucidate the mechanisms that contribute to the development of each regime at the cellular and tissue levels. We study the dynamics of tumor growth in the absence of immune cells. Then, we consider the immune response and we quantify the effects of immunosuppression and local EGF concentration on the fate of the tumor. Numerical simulations of the two models show the existence of three possible outcomes of the tumor-immune interactions in the lymph node that coincide with the main phases of the immunoediting process: tumor elimination, equilibrium, and tumor evasion. Both models predict that the administration of EGF can promote the elimination of the secondary tumor by PD-1/PD-L1 blockade.

Mathematical modeling of tumor-immune system interactions: the effect of rituximab on breast cancer immune response

A mathematical model of tumor-immune interactions incorporated with danger model

A Mathematical Model of TCR-T Cell Therapy for Cervical Cancer

Investigating the synergistic effects of immunotherapy and normalization treatment in modulating tumor microenvironment and enhancing treatment efficacy

Mathematical modeling to elucidate brain tumor abrogation by immunotherapy with T11 target structure

A mathematical model for growth of solid tumors and combination therapy with an application to colorectal cancer

Mathematical modeling of cancer immunotherapy for personalized clinical translation

Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment

Mathematical model of tumor immune microenvironment with application to the combined therapy targeting the PD-1/PD-L1 pathway and IL-10 cytokine antibody

A biomathematical model of tumor response to radioimmunotherapy with $α$PDL1 and $α$CTLA4

Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy

A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour CD8+ T cell immune response

Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment

A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach

Mathematical modeling of combined therapies for treating tumor drug resistance

A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences

A Mathematical Model of Thyroid Disease Response to Radiotherapy

Data-based modeling of breast cancer and optimal therapy

Mathematical Modeling Reveals That the Administration of EGF Can Promote the Elimination of Lymph Node Metastases by PD-1/PD-L1 Blockade

Agent-based modeling of tumor-immune interactions reveals determinants of final tumor states

Data-driven mathematical modeling and quantitative analysis of cell dynamics in the tumor microenvironment